Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor targeting multiple receptor tyrosine kinases, including VEGFRs and HGFR/Met, with IC₅₀ values in the 0.4–9.6 nmol/L range (Schwartz 2022). It robustly inhibits tumor cell proliferation and migration in models such as B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cells. Cellular MET inhibition occurs at 21–23 nmol/L, and in vivo oral dosing at 30 mg/kg reduces metastatic tumor burden in ovarian cancer xenografts. Foretinib is insoluble in water and ethanol but is soluble at ≥31.65 mg/mL in DMSO. The compound is intended exclusively for research, not clinical or diagnostic use (APExBIO).

Biological Rationale

Cancer progression involves dysregulation of receptor tyrosine kinase (RTK) signaling, leading to abnormal cell growth, angiogenesis, and metastasis. VEGFR and HGF/Met pathways are central in tumor angiogenesis and cell motility (Schwartz 2022). Multikinase inhibitors, such as Foretinib, provide a means to simultaneously disrupt multiple oncogenic signals. This multi-target approach addresses tumor heterogeneity and resistance mechanisms observed with single-target agents. Foretinib’s inhibition of VEGFR2 (KDR), VEGFR3 (Flt-4), and MET makes it a valuable tool for dissecting angiogenic and metastatic cascades in cancer research (see also—this article extends by providing detailed IC₅₀ and workflow integration data not covered in the mechanistic overview).

Mechanism of Action of Foretinib (GSK1363089)

Foretinib functions as an ATP-competitive inhibitor of multiple RTKs. It blocks the kinase activity of VEGFR2/KDR, VEGFR3/Flt-4, VEGFR1/Flt-1, MET (HGFR), Ron, KIT, Flt-3, PDGFR-α/β, and Tie-2 with IC₅₀ values between 0.4 and 9.6 nmol/L under biochemical assay conditions (APExBIO). In cellular assays, Foretinib inhibits MET phosphorylation at 21–23 nmol/L. Mechanistically, it suppresses HGF-induced cell motility, induces G2/M cell cycle arrest, and reduces proliferation in various tumor cell lines. By preventing VEGF- and HGF-driven signaling, Foretinib interrupts tumor angiogenesis, cell survival, and migration (compare—this article provides explicit in vitro/in vivo benchmarks and workflow specifics not found in the summary guide).

Evidence & Benchmarks

• Foretinib inhibits recombinant VEGFR2 kinase activity with an IC₅₀ of 0.4 nmol/L (APExBIO datasheet, product page).
• Cellular MET inhibition (measured by phosphorylation) occurs at 21–23 nmol/L in PC-3 and B16F10 cells (Schwartz 2022, Table 3.2).
• Foretinib suppresses tumor growth and migration in A549 (lung), HT29 (colon), and B16F10 (melanoma) cell lines at nanomolar concentrations (Schwartz 2022, Methods).
• Oral administration at 30 mg/kg reduces metastatic tumor nodules and tumor weight in ovarian cancer xenograft models in mice (Schwartz 2022, Results).
• Compound is soluble at ≥31.65 mg/mL in DMSO but is insoluble in water and ethanol (APExBIO, product page).
• Foretinib induces G2/M cell cycle arrest and blocks HGF-driven cell motility, as quantified by scratch wound and transwell migration assays (Schwartz 2022, Figure 4.1).

Applications, Limits & Misconceptions

Foretinib is primarily used to study VEGFR and HGF/Met signaling, cell motility, and angiogenesis in tumor models. It is suitable for both in vitro and in vivo assays, including cell proliferation, migration/invasion, and xenograft metastasis studies. The compound is not approved for human clinical or diagnostic use (APExBIO).

Common Pitfalls or Misconceptions

• Foretinib is not soluble in water or ethanol; attempting dissolution in these solvents leads to precipitation and assay artifacts.
• The product is intended exclusively for scientific research; it is not for therapeutic, diagnostic, or veterinary use.
• IC₅₀ values are cell type- and assay-dependent; direct extrapolation between systems may not be valid.
• Prolonged storage of DMSO stock solutions at above -20°C can result in degradation and loss of potency.
• Off-target effects may occur at higher concentrations due to broad RTK inhibition; controls are necessary for specificity.

This article provides explicit experimental and solubility parameters, extending the concise mechanistic focus in ToloxatoneCompounds.

Workflow Integration & Parameters

For in vitro assays, dissolve Foretinib at ≥31.65 mg/mL in DMSO. Prepare working dilutions in culture medium immediately before use to minimize compound degradation. Store stock solutions at -20°C, protected from light. For cell-based assays, typical working concentrations range from 10–100 nmol/L, depending on the target and cell line. For in vivo mouse studies, oral dosing at 30 mg/kg has demonstrated efficacy in xenograft models without overt toxicity (Schwartz 2022). Always include vehicle (DMSO) and positive control arms. Use fractional viability and relative viability metrics to capture both cytostatic and cytotoxic responses (see detailed methodology).

Foretinib’s multi-target profile facilitates combinatorial studies with cytotoxic agents or immunotherapies. Refer to the A2974 product page for detailed protocol recommendations. For additional strategic guidance, consult this advanced workflow article—this article adds exact solubility and in vivo parameters to its focus on cell motility assays.

Conclusion & Outlook

Foretinib (GSK1363089) is a valuable research tool for dissecting VEGFR and HGF/Met-driven tumor biology. Its nanomolar potency, multi-target specificity, and robust in vivo efficacy make it suitable for advanced cancer research models. Future directions include integration with systems biology approaches and combinatorial regimens. Foretinib is supplied by APExBIO for research use only. For comprehensive data, visit the official product page.